Gossamer Bio Reveals Inducement Grant Compliant with Nasdaq Listing Rule 5635(c)(4)
A clinical-stage biopharmaceutical company, specializing in the advancement and market introduction of seralutinib for the management of pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD),…
Financial Performance Update: Revelation Biosciences, Inc. for Q1 2024
Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences firm dedicated to leveraging trained immunity for disease prevention and treatment, released its financial results for the three months ending March…
Evolus Discloses Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
A leading performance beauty enterprise, specializing in curating an aesthetic range of consumer brands, has announced the allocation of non-qualified stock options for the acquisition of a combined total of…
Mirum Pharmaceuticals Announces Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) disclosed today that its Compensation Committee, a part of Mirum’s Board of Directors, has authorized the allocation of inducement awards to 11 new recruits under…
Progress on Proposed Pandemic Agreement Ahead of World Health Assembly
Today, governments worldwide have reaffirmed their commitment to advancing a proposed pandemic agreement, aiming to refine the draft in preparation for the Seventy-seventh World Health Assembly commencing on May 27,…
Neurocrine Biosciences Unveils CAHtalyst™ Adult Study Findings at AACE 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) revealed today its plans to showcase pivotal findings from the CAHtalyst™ Adult Phase 3 clinical study, shedding light on baseline characteristics of adults grappling with…
Viatris’s First Quarter 2024 Financial Performance Shows Strength, Reaffirms 2024 Financial Outlook
Viatris has just announced its financial outcomes for the initial quarter of 2024, showcasing sustained progress and the robustness of its core operations. Executive Insights Scott A. Smith, CEO of…
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Strike Exclusive Global Licensing Deal for MZE001, a Promising New Treatment for Pompe Disease
Shionogi & Co., Ltd. (based in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (headquartered in South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have finalized an…
argenx Unveils Financial Performance for Q1 2024 Along with Business Update
argenx, a global leader in immunology dedicated to enhancing the lives of individuals grappling with severe autoimmune disorders, has unveiled its financial results for the first quarter of 2024 along…
Survey by CVS Health® Reveals Escalating Concerns in Mental Health
CVS Health® Survey Highlights Growing Mental Health Concerns A recent survey conducted by CVS Health® (NYSE: CVS) in collaboration with Morning Consult reveals an alarming trend: concerns about mental health…
Bristol Myers Squibb Releases Latest Findings from Phase 3 CheckMate -73L Trial
Bristol Myers Squibb (NYSE: BMY) has provided an update on its Phase 3 CheckMate -73L trial, revealing that it did not achieve its primary endpoint of progression-free survival (PFS) in…
Sanofi and Novavax Forge Co-Exclusive Licensing Deal to Co-Market COVID-19 Vaccine and Innovate Flu-COVID-19 Combination Vaccines
Sanofi, in its pursuit of a robust vaccine portfolio, has forged a co-exclusive licensing agreement with Novavax, a biotech firm headquartered in Maryland, USA. The terms of this agreement encompass…